Cogent Biosciences, Inc. — Form 10-K Summary
Reporting period: Fiscal year ended December 31, 2022. Although the request identifies 2022 Q4, this filing reports full-year results, not standalone fourth-quarter results. Cogent is a clinical-stage biotechnology company developing precision therapies; it had no approved products and no product-sales revenue.
Financial and operating performance
| Metric | 2022 | 2021 |
|---|---|---|
| Revenue from product sales | None | None |
| Research and development expense | $121.6 million | $55.9 million |
| General and administrative expense | $26.2 million | $19.6 million |
| Total operating expenses | $147.8 million | $75.6 million |
| Net loss | $140.2 million | $72.3 million |
| Net loss per share, basic and diluted | $2.39 | $1.87 |
| Net cash used in operating activities | $118.6 million | $58.8 million |
| Net cash provided by financing activities | $163.6 million | $38.0 million |
Liquidity: At year-end, cash and cash equivalents were $139.9 million and marketable securities were $119.4 million, totaling $259.3 million. Management estimated these resources would fund operating expenses and capital requirements into 2025, based on assumptions that may prove inaccurate. Current assets were $265.0 million and current liabilities were $26.8 million.
Debt and obligations: The filing does not report conventional borrowings. Operating lease liabilities totaled $19.6 million, including $1.4 million current; undiscounted future minimum lease payments were $30.5 million. Cogent reported $1.7 million in contingent value right (CVR) liability.
Margins: Not meaningful because the company had no product revenue. Accumulated deficit was $411.2 million. Stock-based compensation was $18.4 million in 2022, versus $11.7 million in 2021.
Material changes and business developments
- Net loss increased by $68.0 million year over year, while R&D expense rose by $65.7 million. The company attributed the increase principally to bezuclastinib clinical development and manufacturing, expanded research programs, higher headcount, and facility and laboratory costs.
- Operating cash use more than doubled year over year. Investing activities used $124.7 million, largely reflecting purchases of marketable securities and property and equipment.
- A June 2022 public offering of common stock and pre-funded warrants generated approximately $161.9 million net. Common shares outstanding increased from 43.8 million at year-end 2021 to 69.9 million at year-end 2022; additional potential dilution includes preferred stock convertible into 20.3 million common shares and stock options.
- Research and development headcount expansion accompanied total employee growth from 77 to 138 during 2022. The company moved its headquarters to Waltham and expanded its Boulder research facilities.
- The company recognized $4.0 million of interest income, up from $0.5 million, reflecting higher average invested balances and interest rates. A $1.4 million reduction in the CVR liability was recorded as other income after a lower estimated probability of receiving Sotio milestone payments.
Programs, outlook, and risks
- Bezuclastinib: The lead candidate targets mutant KIT and is being studied in systemic mastocytosis (SM) and gastrointestinal stromal tumors (GIST). APEX, a Phase 2 trial in advanced SM, reported interim results based on a small cohort: 16 patients had been treated by the October 26, 2022 cutoff. The filing reported an 89% objective response rate among TKI-therapy-naive evaluable patients under stated response criteria, and a 73% rate among all patients; results are preliminary and may change as data mature.
- In APEX, the company reported reductions in disease-burden markers and said bezuclastinib was generally well tolerated at the studied doses. Reported treatment-related Grade 3 events included neutropenia, thrombocytopenia, anemia, and hypersensitivity/mediator flare. Small patient numbers limit conclusions about efficacy and safety.
- SUMMIT: The Phase 2 trial in non-advanced SM was enrolling. Management expected initial clinical data in the second half of 2023; European regulatory approvals to initiate the trial were received in March 2023.
- PEAK: The randomized Phase 3 GIST trial compares bezuclastinib plus sunitinib with sunitinib alone. Management expected updated lead-in cohort data in the first half of 2023. Historical Phase 1/2 combination data in a subset of 15 heavily pretreated patients included a 20% confirmed response rate and estimated median progression-free survival of 12 months; these are not Phase 3 results.
- Management expected to assess initiation of APEX Part 2 in mid-2023, and to begin clinical trials for preclinical FGFR2 and ErbB2 programs in 2024. These are forward-looking expectations, not guaranteed outcomes.
- Key risks include clinical-trial failure or delay, patient-enrollment challenges, uncertain regulatory approval and market size, competition, need for substantial additional capital, and dependence on third parties. Bezuclastinib API and drug product relied on single-source suppliers, with no long-term supply agreements. The company also warned that additional financing could dilute shareholders or require concessions on product rights.
- Cogent reported no material legal proceedings and no off-balance-sheet arrangements. The auditor issued an unqualified opinion on the financial statements. Management concluded disclosure controls and internal control over financial reporting were effective; the auditor did not attest to internal controls because of the company’s emerging-growth-company exemption.
Important facts for investors to verify
- Whether the reported cash runway into 2025 remains achievable as clinical-trial and operating costs rise, and what financing may be needed.
- Updated APEX, SUMMIT, and PEAK results, including enrollment, response durability, safety, statistical significance, and regulatory plans.
- Whether supplier redundancy and commercial-scale manufacturing capacity are established for bezuclastinib.
- Potential dilution from outstanding preferred shares, warrants, options, and available shelf or at-the-market financing capacity.
- The status and value of Plexxikon milestone and royalty obligations, and the remaining CVR liability and Sotio-related milestones.